Display Settings:

Format

Send to:

Choose Destination
See comment in PubMed Commons below
Future Med Chem. 2010 Aug;2(8):1273-82. doi: 10.4155/fmc.10.221.

Challenges of Phase III study design for trials of new drug regimens for the treatment of TB.

Author information

  • 1Medical Research Council Clinical Trials Unit, 222 Euston Road, London, NW1 2DA, UK. patrick.phillips@ctu.mrc.ac.uk

Abstract

The standard WHO-recommended 6-month four-drug regimen for the treatment of tuberculosis is highly effective in clinical trial settings, but this level of efficacy is not always achieved in practice. Shorter, simpler regimens that promote better treatment adherence are urgently needed. In addition, it will be necessary to demonstrate noninferiority rather than superiority over the 6-month regimen. There are considerable challenges in designing and conducting noninferiority Phase III trials of new drug regimens. These include the choice of the margin of noninferiority, the primary outcome measure and strategies for handling nonassessable patients and reinfected patients in the analysis. Most of these trials are likely to be large and expensive and public-private partnerships will be required to conduct them.

PMID:
21426018
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Icon for Atypon
    Loading ...
    Write to the Help Desk